The goal of this clinical trial is to compare the pharmacokinetic profile of the single intravenous injection of the test product and reference product in healthy subjects and to evaluate the bio-equivalence and safety of these two injections in healthy subjects. The main questions it aims to answer are:
[Question 1] Is there significant difference in the pharmacokinetic profile between the Iron Sucrose Injection (100 mg/5 mL [calculated by iron]) manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd. and the Iron Sucrose Injection (trade name: Venofer®, 100 mg/5 mL [calculated by iron]) held by Vifor France? [Question 2] Is it safe for the healthy subjects to take the test product (100 mg/5 mL [calculated by iron]) manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd. and the reference product held by Vifor France? Participants will be randomly divided into group I and group II, with equal number of subjects in each group. Each subject will receive only one dose of either the test product or the reference product in each period (two-sequence crossover study).

Start Date20 Nov 2024

Sponsor / Collaborator

Sichuan Huiyu Pharmaceutical Co., Ltd.

[+2]

CTR20244071

/ Active, not recruitingNot Applicable

蔗糖铁注射液人体生物等效性研究

[Translation] Study on bioequivalence of iron sucrose injection in healthy volunteers

主要目的：本试验旨在研究健康受试者单次静脉注射四川汇宇制药股份有限公司研制、生产的蔗糖铁注射液（5 ml:100 mg铁和1.6 g蔗糖）在健康受试者体内的药代动力学特征；以Vifor France持证的蔗糖铁注射液（Venofer®，5 ml:100 mg铁）为参比制剂，比较两制剂中药动学参数的差异，评价两制剂的人体生物等效性。次要目的：评估受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: This study aims to study the pharmacokinetic characteristics of a single intravenous injection of iron sucrose injection (5 ml: 100 mg iron and 1.6 g sucrose) developed and produced by Sichuan Huiyu Pharmaceutical Co., Ltd. in healthy subjects; using Vifor France's certified iron sucrose injection (Venofer®, 5 ml: 100 mg iron) as the reference preparation, compare the differences in pharmacokinetic parameters between the two preparations, and evaluate the human bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation and the reference preparation in healthy subjects.

Start Date18 Nov 2024

Sponsor / Collaborator

Sichuan Huiyu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Iron sucrose

100 Translational Medicine associated with Iron sucrose

100 Patents (Medical) associated with Iron sucrose

1,210

Literatures (Medical) associated with Iron sucrose

07 Jan 2025·CURRENT PHARMACEUTICAL DESIGN

Utilizing Plant Phytoconstituents in Metal Oxide Nanoparticle Synthesis for Cancer Therapies

Article

Author: Virmani, Tarun ; Gugulothu, Dalapathi ; Sharma, Ashwani ; Dubey, Swati ; Kumar, Girish ; Yadav, Shiv Kumar

Background::

The metal oxide nanoparticles possess unique properties such as biological compatibility, superior reactivity, and capacity to develop reactive oxygen species, due to this they have drawn significant interest in cancer treatment. The various MONPs such as cerium oxide, Copper oxide, Iron oxide, Titanium dioxide, and Zinc oxide have been investigated for several types of cancers including brain, breast, cervical, colon, leukemia, liver, lung, melanoma, ovarian, and prostate cancers. However, traditional physiochemical synthetic methods for MONPs commonly include toxic materials, a major concern that raises questions regarding their biocompatibility and safety.

Objective::

This study aims to investigate the role of plant phytoconstituents in the development of MONPs via green synthesis and explore the therapeutic effectiveness of MONPs in treating several types of cancer. Primarily, it examines the potential of plant phytoconstituents (phenolic compounds, flavonoids, glycosides, alkaloids, etc.) in the development of MONPs as well as their improved ability to target numerous types of cancer.

Methods::

A systemic search was conducted on recent literature, focusing on developing green MONPs by utilizing plants' phytoconstituents (plant extracts). The study of plant phytochemicals (present in different parts of a plant such as leaves, flowers, stems, peels, and roots) and their role in the synthesis of green metal oxide nanoparticles as well as their anticancer activity against several types of cancers was analyzed. Also focusing on their anticancer mechanism that involves ROS production, generates oxidative stress, and apoptosis leads to cancer inhibition.

Results::

Phytochemicals-mediated metal oxide nanoparticle synthesis revealed many advantages such as improved biological compatibility and enhanced sensitivity towards cancer cells. Phytochemicals present in plant extracts act as natural capping, reducing, and stabilizing agents, enhancing nanoparticle synthesis which leads to synergistic anticancer activity. Additionally, the natural antioxidant and anticancer activity of various phytochemicals enhances the therapeutic potential of metal oxide nanoparticles, producing them more effective against ROS-generated apoptosis and showing negligible toxicity towards normal cells.

Conclusion::

The utilization of plant phytochemicals in metal oxide nanoparticle production presents a safe, eco-friendly, sustainable, and effective approach to developing effective and safer cancer nanomedicines. Green synthesis not only increases anticancer activity but also decreases the biocompatibility problems associated with the physiochemical synthetic approach. Further research needs to concentrate on improving this synergy to create a targeted phytochemical-based metal oxide nanoparticle for cancer therapeutics.

01 Jan 2025·Hemodialysis International

Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta‐analysis

Review

Author: Georgopoulos, Christos ; Dounousi, Evangelia ; Gouva, Charikleia ; Kitsos, Athanasios ; Duni, Anila ; Stamellou, Eleni

Abstract:

Introduction:

Phosphate binders are commonly used in patients receiving kidney replacement therapy (KRT), aiming to reduce and maintain serum phosphorus. Chronic kidney disease‐mineral and bone disorder has been linked to reduced lifespan and worsened quality of life. This study aims to examine the efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate in patients receiving KRT.

Methods:

The data sources examined were MEDLINE (PubMed), Scopus, and the Cochrane Central Register of Controlled Clinical Trials with a search deadline of October 2023. We examined randomized controlled trials that compared sucroferric oxyhydroxide versus sevelamer carbonate in the adult population receiving KRT. We performed a meta‐analysis combining the data from trials, using R‐studio.

Findings:

Inclusion criteria were met by five randomized trials. There was no statistically significant difference in the reduction of serum phosphorus between the two groups (MD: −0.07 mmol/L, 95% CI‐random effects: −0.15 to 0.02). In the same line, a non‐statistically significant difference was observed in serum i‐PTH reduction between the two drugs (MD = −1.53 mg/dL, 95% CI = (−4.45, 1.4), p = 0.26, random effects model). No statistically significant difference was observed in all adverse events between the two groups (odds ratio: 1.11, 95% CI: 0.65–1.88, random effects model). Further analysis of gastrointestinal adverse events revealed that sevelamer carbonate increases gastrointestinal adverse events by up to 60% (odds ratio: 1.60, 95% CI: 1.31–1.97, common (fixed) effect model).

Discussion:

This meta‐analysis of randomized trials showed that both drugs, sucroferric oxyhydroxide and sevelamer equally and effectively controlled serum phosphorus levels, whereas sucroferric oxyhydroxide revealed a better profile in terms of gastrointestinal adverse events. Sucroferric oxyhydroxide is a valuable option for patients receiving KRT when sevelamer carbonate is more difficult to tolerate.

01 Jan 2025·SCIENCE OF THE TOTAL ENVIRONMENT

Effects of coexisting goethite or lepidocrocite on Fe(II)-induced ferrihydrite transformation pathways and Cd speciation

Article

Author: Yin, Meiling ; Zhou, Yuting ; Yang, Chen ; Li, Xiaofei ; Zhong, Qiaohui ; Zeng, Lijuan ; Guo, Chuling ; Dang, Zhi ; Li, Xin

The efficacy of ferrihydrite in remediating Cd-contaminated soil is tightly regulated by Fe(II)-induced mineralogical transformations. Despite the common coexistence of iron minerals such as goethite and lepidocrocite, which can act as templates for secondary mineral formation, the impact of these minerals on Fe(II)-induced ferrihydrite transformation and the associated Cd fate have yet to be elucidated. Herein, we investigated the simultaneous evolution of secondary minerals and Cd speciation during Fe(II)-induced ferrihydrite transformation in the presence of goethite versus lepidocrocite. The presence of goethite resulted in a more pronounced ferrihydrite transformation than lepidocrocite because goethite facilitates electron transfer. Coexisting goethite promoted the production of secondary goethite with different morphology by triggering template-directed nucleation and growth of labile Fe(III) derived from ferrihydrite and intermediate lepidocrocite, respectively. However, coexisting lepidocrocite impeded goethite formation from ferrihydrite and acted as the template to facilitate secondary lepidocrocite production. Furthermore, variations in the crystallinity of coexisting lepidocrocite influenced the particle size and crystallinity of the secondary lepidocrocite, reflecting different dominant mechanisms in secondary lepidocrocite formation. Despite partial Cd mobilization into the solution due to Fe(II)-induced ferrihydrite transformation, secondary goethite and lepidocrocite re-sequestered Cd through lattice Fe(III) substitution, indicated by an increased structural Cd proportion, expanded lattice spacing, and reduced hyperfine field intensity. Additionally, secondary goethite was more effective than secondary lepidocrocite in sequestering Cd. Coexisting goethite increased the structural Cd proportion by 3.5-fold compared to coexisting lepidocrocite, demonstrating the superior ability of coexisting goethite in enhancing Cd stability during Fe(II)-induced ferrihydrite transformation in natural soils. These findings highlight the impact of template-driven mineralogical transformation on Cd fate in polluted soils and provide crucial implications for toxic metal remediation using mineral amendments.

News (Medical) associated with Iron sucrose

09 Oct 2024

·www.prnewswire.com

Renibus Therapeutics Announces Oral Presentation on RBT-1 at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

- Renibus is actively enrolling a Phase 3 pivotal trial to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - SOUTHLAKE, Texas, Oct. 9, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced that an oral presentation will be delivered on RBT-1 at the 38th EACTS Annual Meeting, taking place October 9-12, 2024, in Lisbon, Portugal. Charles Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery and Vice Chairman of Quality and Patient Safety, New York-Presbyterian Hospital, Weill Cornell Medicine, will be presenting on behalf of Renibus. RBT-1 is a single-dose, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing non-emergent cardiac and/or valve surgery. Renibus is actively enrolling a Phase 3 pivotal trial of RBT-1 to reduce the risk of post-operative complications and improve outcomes following cardiac surgery. RBT-1 has received Breakthrough and Fast Track Designations from the US FDA. "We are thrilled that EACTS has recognized RBT-1 with an oral presentation to share our promising results with the global cardiothoracic surgery community," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "Enrollment in the RBT-1 Phase 3 PROTECT study is ahead of schedule, and we remain on track to report top-line data in the second quarter of 2025." "RBT-1 has shown great potential in our Phase 2, multi-center, randomized, double-blind, placebo-controlled study," said Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine. "I am excited to present new data from a post-hoc analysis, which included all patients regardless of surgery delay, showing that the improvement in clinical outcomes in response to RBT-1 treatment was maintained." Details of the oral presentation at EACTS Annual Meeting: Title: Effect of RBT-1 on Clinical Outcomes the Safety Population of a Phase 2 Study in Cardiac Surgery Date and Time: Friday, October 11, 2024, 9:15 am Presenting Author: Charles Mack, MD Authors: C. Mack (New York, USA), M. Jessen (Dallas, USA), A. Shaw (Cleveland, USA), S. Ruiz (Southlake, USA), C. Wang (Piscataway, USA), S. Snapinn (Seattle, USA), B. Singh (Southlake, USA), A. Lamy (Ontario, Canada) About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory and antioxidant pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Phase 3Fast TrackBreakthrough Therapy

24 Sep 2024

·www.prnewswire.com

Renibus Therapeutics Announces Participation at Upcoming Investor Conferences

SOUTHLAKE, Texas, Sept. 24, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced participation in the following upcoming investor conferences: Oppenheimer Private Life Sciences Company Showcase, October 1, 2024, New York, NY 4th Annual Needham Private Biotech Company Virtual 1x1 Forum, October 8-9, 2024 Renibus management will be available to meet with investors one-on-one during these events. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Fast TrackAcquisition

26 Apr 2024

·www.prnewswire.com

Renibus Therapeutics Announces Oral Presentations on RBT-1 at AATS and SCA Medical Conferences

SOUTHLAKE, Texas, April 26, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation at two prestigious medical conferences: the American Association for Thoracic Surgery (AATS) 104th Annual Meeting and the Society of Cardiovascular Anesthesiologists (SCA) 46th Annual Meeting, both taking place in Toronto, Canada, April 27-30, 2024. "We are pleased to present additional clinical data on RBT-1 at the AATS and SCA meetings in collaboration with key opinion leaders in our field, Drs. Charles Mack and Andrew Shaw," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "These presentations are critical to advancing the understanding of our preconditioning approach with RBT-1, and we thank the meeting organizers and principal investigators for their partnership. Our Phase 3 PROTECT study is enrolling well and we remain on track to report top-line data in the third quarter of 2025." RBT-1 (stannic protoporfin / iron sucrose) is a single dose, multi-organ, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing cardiac surgery.Renibus Therapeutics is actively enrolling its PROTECT Phase 3 pivotal trial evaluating RBT-1's potential to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. RBT-1 has received both FDA Breakthrough and Fast Track Designations. Details of the oral presentations at AATS: Title: RBT-1 Reduces Incidence of Blood Product Utilization in Patients Undergoing Non-Emergent Coronary Artery Bypass Grafting and/or Valve Surgery Date and Time: Sunday, April 28th at 9:44 am ET Location: Room 714 Presenter: Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine Title: RBT-1 Reduces the Number of Post-Operative Complications Associated with Cardiac Surgery Date and Time: Sunday, April 28th at 4:03 pm ET Location: Theater 2, Exhibit Hall Presenter: Bhupinder Singh, MD, Chief Medical Officer, Renibus Details of the oral presentation at SCA: Title: RBT-1 Improves Clinical Outcomes in Patients Requiring Prolonged Intensive Care Unit Stay Following Non-Emergent Cardiac Surgery Date and Time: Sunday, April 28th at 3:00 pm ET Session: Best of Meeting Oral Presenter: Andrew Shaw, MD, FRCA, FCCM, FFICM, Professor and Chair, Department of Intensive Care and Resuscitation, Cleveland Clinic About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory andantioxidant pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics

Phase 3Fast TrackPhase 2Breakthrough Therapy

100 Deals associated with Iron sucrose

External Link

KEGG	Wiki	ATC	Drug Bank
D04616	Iron sucrose	B03AB02	DB09146

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kidney Failure, Chronic	CA	Vifor Fresenius Medical Care Renal Pharma Ltd.	05 Jan 2018
Hyperphosphatemia	JP	Kissei Pharmaceutical Co., Ltd.	28 Sep 2015
Chronic Kidney Diseases	US	American Regent, Inc.	06 Nov 2000
Iron deficiency	US	Sanofi-Aventis U.S. LLC	25 Apr 1957
Anemia, Iron-Deficiency	CH	Vifor Pharma AG	02 Jun 1949

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 3	-	American Regent, Inc.	01 Feb 2003
Anemia	Phase 3	-	American Regent, Inc.	01 Jul 2002
Inflammatory Bowel Diseases	Phase 2	US	American Regent, Inc.	01 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04485039 (CTgov)	Phase 4	Smallpox	44	Tecovirimat (TPOXX: Oral Antiviral)	kturnzijnw(vesanferyi) = zvniggceqe pvseeabrdv (kbepesrvcj, cugtijcjcu - rktzcnxtem) View more	-	09 Oct 2024
				Tecovirimat+sevelamer carbonate oral tablet (TPOXX: Oral Antiviral and Sevelamer Carbonate)	cbembduuse(afjrzwtgqn) = gobddeuxwb oewoyyqpqf (dudvaduuuh, vpqunnubrx - vdwricgqxh) View more
SOHO2024	Not Applicable	Hypophosphatemia	-	Ferric hydroxide-sucrose	uynltptsry(qfhhovzqos) = oxwymxsmsf vuohrwsudh (qivwyfclga )	-	04 Sep 2024
SOHO2023	Not Applicable	-	-	Ferric Carboxymaltose (FCM)	etlxjngnio(ioqnrxddhr): risk ratio = 0.97 (95% CI, 0.62 - 1.51), P-Value = 0.86 View more	-	01 Sep 2023
				Iron Sucrose (IS)
DaVita Biorepository (ASN2022)	Not Applicable	iron sucrose	950	Iron Sucrose administration	ipwrgnolfl(xzburcyjwf) = rstysfzzim ftljtqtbjz (vexmmazsep )	Positive	05 Nov 2022
				No Iron Sucrose administration	-
ASN2022	Not Applicable	sP \| sCa \| iPTH	100	Sucroferric oxyhydroxide	cnphexuhdi(vhocumcvkw) = blveddbsty lwbsnvcybw (cpjbmwwpet )	Positive	03 Nov 2022
NCT04046263 (CTgov)	Phase 4	Hyperphosphatemia \| Peritoneal dialysis complication \| Hypoalbuminemia	17	Sucroferric Oxyhydroxide Chewable Tablet	jfchaexxmm(fojjiribuv) = rhqewraigl msocxwnwrr (udkguuoaea, hjllcyeuvz - nxmcliikzx) View more	-	31 Aug 2022
MO809 (ERA2022)	Not Applicable	Hyperphosphatemia	92	Sucroferric Oxyhydroxide	bbmtenpqco(gmwkrlxucl) = The drug was well tolerated yesucglajq (vtcbekclis ) View more	Positive	03 May 2022
ERA2022	Not Applicable	Bone Diseases FGF23 \| soluble Klotho \| c-reactive protein (CRP) ... View more	50	Sucroferric oxyhydroxide	loatwzpbxf(dxmvwkmjap) = zalccbbzsm kbdjzxxlaj (pegrsbxgjq ) View more	Positive	03 May 2022
				Sevelamer	wzfharqsik(lfhnfwrovk) = kylwmwdguu tsattdflmc (gxncnekzlg )
ERA2022	Not Applicable	Chronic Kidney Diseases skeletal plasma clearance of tracer (K i ) \| bone volume/tissue volume (BV/TV)	-	Sucroferric oxyhydroxide	enufmkffgo(ydhqfljwub) = BV/TV (volume) was significantly lower after SO treatment than after CC treatment lksjhrstwf (prbktqhobr )	-	03 May 2022
				Calcium carbonate
ASN2021	Not Applicable	-	17	Sucroferric oxyhydroxide (SO)	lapabnspqd(oybqfrmxnl) = wplcepfmse pdsyqualcc (jqovnnfrqt ) View more	Positive	27 Oct 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Iron sucrose

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation